Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Lenacapavir for HIV prevention remains investigational and is not approved anywhere globally. Phase 1 studies indicate promising results for once-yearly use. However, further research, including ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Since 2018, three medications have been approved by the FDA for use in heavily treatment-experienced or treatment-resistant HIV: ibalizumab, fostemsavir and lenacapavir.

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Called lenacapavir, the medicine caused a stir because ... but compliance is spotty and there is a stigma attached to regularly taking an HIV drug. But the impact the Gilead drug may have on ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...